ChiCTR2100048879 版本V1.0 版本创建时间2022/03/06 12:38:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048879 

最近更新日期:

Date of Last Refreshed on:

2021-07-19 01:05:32 

注册时间:

Date of Registration:

2021-07-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

ICL手术与SMILE手术术后患者视觉质量及调节功能的观察研究

Public title:

Observation of visual quality and regulation function of patients after ICL surgery and SMILE surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

ICL手术与SMILE手术术后患者视觉质量及调节功能的观察研究

Scientific title:

Observation of visual quality and regulation function of patients after ICL surgery and SMILE surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

耿钊 

研究负责人:

叶剑 

Applicant:

Zhao Geng 

Study leader:

Jian Ye 

申请注册联系人电话:

Applicant telephone:

18602358024

研究负责人电话:

Study leader's
telephone:

13708385175

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

524450744@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yejian1979@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区长江支路10号

研究负责人通讯地址:

重庆市渝中区长江支路10号

Applicant address:

Changjiang zhilu No.10, Yuzhong district, Chongqing

Study leader's address:

No. 10, Changjiang Branch Rd, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

陆军特色医学中心(大坪医院)

Applicant's institution:

陆军特色医学中心(大坪医院)

研究负责人所在单位:

陆军特色医学中心(大坪医院)

Affiliation of the Leader:

陆军特色医学中心(大坪医院)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医研伦审(2021)第103号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国人民解放军陆军特色医学中心伦理委员会

Name of the ethic committee:

The Ethics Committee of the PLA Army Specialized Medical Center

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

王晶晶

Contact Name of the ethic committee:

Jingjing Wang

伦理委员会联系地址:

重庆市渝中区长江支路10号

Contact Address of the ethic committee:

Changjiang zhilu No.10, Yuzhong district

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

陆军特色医学中心眼科

Primary sponsor:

Department of Ophthalmology, Army Special Medical Center

研究实施负责(组长)单位地址:

重庆市渝中区长江支路10号

Primary sponsor's address:

Changjiang zhilu No.10, Yuzhong district

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军特色医学中心(大坪医院)

具体地址:

渝中区长江支路10号

Institution
hospital:

Army Specialized Medical Center (Daping Hospital)

Address:

10 Changjiang Branch Road, Yuzhong District

经费或物资来源:

Source(s) of funding:

no funding

研究疾病:

屈光不正  

Target disease:

Refractive erro

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

(一) ICL手术对不同年龄阶段患者的调节功能的影响研究 (二) ICL术后患者与SMILE术后患者视觉质量及调节功能的比较  

Objectives of Study:

(1) Study on the effect of ICL surgery on the regulatory function of patients at different ages (2) Comparison of visual quality and regulation function between ICL patients and SMILE patients

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(一) ICL手术对不同年龄阶段患者的调节功能的影响研究
纳入标准:
(1)≥18岁
(2)屈光度稳定2年及以上
(3)屈光度:球镜≥-15.00D,散光≤5.00D,屈光参差≤2.00D
(3)最佳矫正视力≥0.8
(4)前方深度≥2.8mm
(5)角膜内皮>2500/mm2
(6)眼位正常
(二) ICL术后患者与SMILE术后患者视觉质量及调节功能的比较
纳入标准
(1)年龄:18~35岁
(2)屈光度:球镜-3.00D~-8.00D,散光≤2.00D,屈光参差≤2.00D
(3)最佳矫正视力≥0.8
(4)前方深度≥2.8mm
(5)角膜内皮>2500/mm2
(6)眼位正常

Inclusion criteria

(1) Study on the effect of ICL surgery on the regulatory function of patients at different ages
Inclusion criteria:
(1) ≥18 years old
(2) Diopter stability for more than 2 years
(3) Refraction: spherical lens ≥-15.00D, astigmatism ≤5.00D, anisometropia ≤2.00D
(3) Best corrected visual acuity ≥0.8
(4) Front depth ≥2.8mm
(5) Corneal endothelial > 2500/mm2
(6) Normal eye position
(2) Comparison of visual quality and regulation function between ICL patients and SMILE patients
Included in the standard
(1) Age: 18-35 years old
(2) Refraction: spherical mirror -3.00D~-8.00D, astigmatism ≤2.00D, anisometropia ≤2.00D
(3) Best corrected visual acuity ≥0.8
(4) Front depth ≥2.8mm
(5) Corneal endothelial > 2500/mm2
(6) Normal eye position

排除标准:

(1)眼前节、眼底器质病变患者
(2)显性斜视患者
(3)眼部手术史患者

Exclusion criteria:

(1) Patients with anterior segment and fundus organ lesions
(2) Patients with dominant strabismus
(3) Patients with a history of eye surgery

研究实施时间:

Study execute time:

From 2021-07-19 00:00:00 To 2023-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-19 00:00:00 To 2022-07-31 00:00:00

干预措施:

Interventions:

组别:

SMILE手术组

样本量:

100

Group:

SMILE group

Sample size:

干预措施:

行SMILE手术

干预措施代码:

Intervention:

SMILE surgery

Intervention code:

组别:

ICL植入组

样本量:

100

Group:

ICL impantation group

Sample size:

干预措施:

ICL植入术

干预措施代码:

Intervention:

ICL impantation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军特色医学中心(大坪医院) 

单位级别:

三级甲等 

Institution
hospital:

Army Specialized Medical Center (Daping Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视力

指标类型:

主要指标

Outcome:

vision

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主观问卷:COVD-Q

指标类型:

主要指标

Outcome:

questionnaire: COVD-Q

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

对比敏感度

指标类型:

次要指标

Outcome:

Contrast sensitivity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

调节功能

指标类型:

主要指标

Outcome:

Regulating function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉质量OPD

指标类型:

主要指标

Outcome:

Visual quality OPD

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 50 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

The random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年10月 http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

10/2022 http://www.medresman.org.cn/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录采用Excel文档,电子采集和管理采用ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel documents were used for case records, and RESMAN was used for electronic collection and management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-19 01:05:32